Brief history of proton therapy I n 1946, Dr. Robert Wilson proposed to use protons in treating cancer. [1] The first proton treatment was administered by Berkeley Radiation Laboratory in 1954. Although several research institutes around the world have conducted proton treatment for tumors with limited depth, the first hospital-based proton center, which has a high energy proton beam to treat a variety of tumors, was established in Loma Linda University at California in 1990. By the end of 2013, more than 25 proton centers in the world had multiple treatment rooms and high energy proton beams to treat deeply seated tumors; more than 100,000 patients were treated by proton beams. The number of proton treatment facilities is expected to rapidly increase due to the introduction of the single-room design. Chang Gung Memorial Hospital-Linkou set up the first proton center in Taiwan and started patient treatment in September 2014.
The physical characteristics and potential clinical benefits of proton beams
X-ray (photons) emitted by a linear accelerator is the most common treatment beam for current radiotherapy. Compared to the proton beam, the X-ray has the disadvantages of a higher entrance dose in front of the tumor and a remarkable residual dose after the tumor, whereas protons pass through tissues with a lower entrance dose, but release large amounts of energy when they reach the desired depth of treatment (the Bragg peak) and deposit no dose to the normal tissues behind the tumor [ Figure 1 ]. Due to this physical characteristic, the proton beam protects normal tissues after the treatment target from radiation damage.
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Since a single Bragg peak is not wide enough to cover a whole tumor, a summation of multiple peaks [Spread-out Bragg Peak (SOBP)] is needed to broaden the coverage to the size of the tumor. The formation of SOBP increases the entrance dose but still maintains a minimal exit dose [ Figure 1 ]. The potential benefits of proton beam in terms of dose distribution are demonstrated in Figure 2 . Figure 2A presents the dose comparisons between proton beam and the most advanced X-ray technique, volumetric modulated arc radiotherapy (VMAT), to a hepatocellular carcinoma (HCC). The low dose bath to normal liver and gastrointestinal tissue in the VMAT is spared in the proton beam. This low dose bath is a determining factor for radiation-induced liver toxicity because normal liver tissues have a poor tolerance to radiation damage. The tolerance is even worse for livers with cirrhosis or viral infection commonly seen in HCC patients at Taiwan. The difference in the low dose bath becomes bigger with the increasing tumor size. Figure 2B shows the dose distribution of intensity-modulated proton therapy (IMPT) versus VMAT in nasopharyngeal carcinoma (NPC). In VMAT, there are substantial doses to the buccal mucosa, tongue, and submandibular and submental regions, which are not considered as treatment targets for NPC. These regions could be effectively spared by IMPT. These advantages in the dose distribution have high possibility to translate into clinical benefits to patients.
Evolution of the proton treatment technique
The conventional proton treatment was mainly given by passive scattering, a technique relatively insensitive to organ motion caused by respiration. Through this technique, sufficient clinical evidence was obtained to show the advantages of proton over X-ray in pediatric CNS tumor, skull base sarcoma, ocular melanoma, liver tumor, and some other tumors. [2] [3] [4] [5] However, this technique has several limitations such as a limited field size, unconformity to the tumor shape in the entrance region, using complex combinations in treating tumors with irregular shapes, requirements of a collimator and a compensator, and slow throughput by multiple field treatment. Due to these limitations and prevalent cancer types, more than 60% of cases in the US proton centers were prostate cancer patients; this application raises a lot of arguments. [6, 7] In 1996, the scanning technique was first employed in proton therapy by the Paul Scherrer Institute (PSI) in Switzerland, but it was not used in other centers before 2009. The development of advanced scanning technique is another milestone for proton therapy, because it has the capability to cover a large field, conduct IMPT, and treat tumors with complex geometry. The best examples for this application are head and neck cancers, in which treatment often needs large fields to cover the primary tumor and neck lymphatics, and tumors which have target shape with complexity and are close to organs at risk.
In 2011, out of 92,682 new patients with invasive cancer in Taiwan, around 35-40% received radiotherapy as part of their cancer treatment, while this figure is up to 60% in the United States. Since proton therapy is an emerging tool for radiotherapy, we should learn its potential benefits for specific cancer types in Taiwan. However, this issue has never been addressed in literature despite our extensive research, and will be discussed in the following sections. 
Primary liver tumor
Taiwan is an endemic region for HCC due to the high prevalence of the carrier status of hepatitis B and/or C infection. In 2011, more than 10,000 patients with primary liver tumor were diagnosed. [8] Surgery, percutaneous ethanol injection therapy (PEIT), radiofrequency ablation (RFA), and transcatheter arterial chemoembolization (TACE) are the major treatments for 25%, 11%, and 27% HCC patients, respectively, in Taiwan. Although RFA is the preferred local treatment for non-surgical patients, incomplete ablation and local relapse rate are associated with increasing tumor size; [9] therefore, RFA is not recommended for tumors larger than 5 cm. [10] Meanwhile, around 80% patients will have intrahepatic relapse within 5 years of surgery or RFA.
Several proton centers in Japan have demonstrated the efficacy of proton therapy on the local tumor control of HCC. A Phase II trial using proton therapy for patients not suitable for surgery or local treatment showed a 96% local progression-free survival rate at 2 years. [11] The local control from other Japanese series ranged from 81 to 95%. [12] [13] [14] The respective local tumor control rates were 96%, 84%, and 43% for tumor size smaller than 5cm, 5-10 cm, and larger than 10 cm, [12] and minimal complication rates were reported from these series. The local tumor control rate was comparable and similar between proton beam and carbon ion. [13] For patients whose tumor had portal vein thrombosis, surgery or local treatment was often difficult to administer, and Sorafenib had only a limited effect on progression-free survival; proton therapy was shown to improve the progression of local tumor and patients' survival rates. [15] [16] [17] The clinical outcome of the proton treatment for HCC reported in the literature is summarized in Table 1 . Based on the conditions mentioned above, our estimation is that around 15-20% of Taiwanese HCC patients might benefit from proton beam treatment.
The treatment protocol for proton beam on HCC varied between centers, but hypofractionated schedule is a standard principle. [12] [13] [14] The fraction number ranges from 5 fractions for small liver tumors as a stereotactic body radiation therapy (SBRT) to 35 fractions for tumors next to the bowel. [14] In general, most centers administer 10-20 fractions, 3.8-6.6 GyE (Gray equivalent) per fraction, and from 63 to 76 GyE for the total dose [ Table 1 ]. 
Head and neck cancers including nasopharyngeal carcinoma
Due to the limitations in the field size and conformity to the tumor, the passive scattering technique needs complex combinations such as patching or matching between fields to treat primary tumors and lymphatics in head and neck tumors. Skull base, paranasal sinus, and parotid gland tumors were the most common head and neck tumors treated by proton beam with passive scattering technique. However, several recent publications not only showed the feasibility of using spot beam scanning technique in delivering IMPT in head and neck cancer [19] [20] [21] but also showed that the preliminary results are very promising. [3, 22] The potential benefits of IMPT in head and neck cancer mainly are due to sparing of normal tissues from the radiation dose. For ipsilateral lesions such as tonsil or buccal cancers, IMPT has a significantly lower dose than intensity-modulated X-ray (IMRT) in contralateral submandibular and parotid gland, oral cavity, spinal cord, and brain stem. [20] For oropharyngeal cancer and nasopharyngeal cancer, the treatment target does not include the brain, oral cavity, submandibular gland, or esophagus. Compared to IMRT, IMPT spares substantial dose to these regions [23] and preliminary results were very encouraging for using this technique. [22] The result of a recent study showed that the percentage of oropharyngeal cancer patients requiring nasogastric tube feeding during concurrent chemoradiotherapy (CCRT) was significantly reduced from 46% by IMRT to 19% by IMPT. [24] The clinical outcome of head and neck cancer patients treated by proton therapy, mainly by passive scattering technique, is summarized in Table 2 .
In 2011, out of 4648 newly diagnosed oral cavity (excluding salivary gland) cancer patients in Taiwan, around 40% received radiotherapy as part of their first-line treatment. [8] There were 1281 and 1579 patients with oropharyngeal and nasopharyngeal cancer, respectively; around 90% of them received radiotherapy as the main treatment. Overall, more than 4000 head and neck cancer patients might benefit from proton treatment; cases with skull base, paranasal sinus, and parotid gland tumors were not counted.
Potential clinical benefits of proton therapy on cancers with high prevalence in Taiwan and in western countries
The leading five cancers in Taiwan in the year 2011 were colon-rectal (N = 14,087), liver (N = 11,292), lung (N = 11,059), breast (N = 10,056), and head and neck (N = 6890; excluding NPC). [8] Other than liver, head, and neck cancers, the rest are also leading cancers in the western countries. Among them, lung and left breast cancers have a greater potential to benefit from proton treatment.
Primary lung cancer
Medically inoperable early-stage and stage III lung cancers are two conditions for proton therapy. The dose to the normal lung is significantly lower for proton beam than for X-ray. [25, 26] The 4-year local control rate and disease-specific survival rate were 96% and 88%, respectively, for peripheral T1 tumors treated by 70 GyE proton beam in 10 fractions. [27] Clinical radiation pneumonitis was not a significant complication under such high-dose treatment by proton beam. None of the patients required steroid therapy for radiation pneumonitis and pulmonary function was well-maintained 1 year after treatment. [27] In studies with doses of 52.8-80 GyE in 4-26 fractions, the local control rate was 81% and 75% for T1 and T2 lung cancer, respectively; and there was no difference between proton and carbon beam in the outcome. [28, 29] Radiation dose was found to be the most significant factor for local control [30] and higher radiation dose could be achieved by using proton beam.
Concurrent chemoradiation is the front line treatment for stage III lung cancer; however, higher radiation doses by X-ray bring more complications but no survival benefit. [31] By employing proton beam, the mean total lung V5, V10, and V20 were significantly reduced, even when the radiation dose was increased from 63 Gy by X-ray to 74 GyE by proton. [25] Several studies showed that proton is a safe tool for dose escalation in stage III lung cancer [25, 32, 33] and the preliminary results are very encouraging.
Left breast cancer
It has been reported that the risk of ischemic heart disease was increased in women with left breast cancer and treated with radiotherapy. [34] [35] [36] The increase is proportional to the mean dose to the heart and continues for at least 20 years. [34] For women with left breast cancer and receiving post-mastectomy radiotherapy by X-ray, it will be a great challenge to reduce the dose to the heart if the internal mammary chain is included in the treatment field. The dosimetric comparisons between X-ray or X-ray/electron and proton beam showed that proton is cardiac-and pulmonary-sparing; [37] a report of early clinical outcome in 12 patients showed that this application of proton therapy is feasible and well tolerated. [38] Proton therapy was also employed for partial breast irradiation in a Phase II trial; [39] however, its clinical benefits need further justification. Proton therapy could be also applied to patients with left breast cancer and treated with breast conserving surgery; however, a good fixation method is needed to maintain positional reproducibility of a large breast.
In Taiwan, the number of cases with invasive cancer of the breast was 10,103 in year 2011; 49% of the patients received radiotherapy as part of their first course treatment.
Cost-effectiveness consideration for proton therapy
Due to the higher capital investment needed for the construction of a proton facility and operating costs, an average course of proton therapy was estimated to be about 2-3 times the cost of IMRT. [48] [49] [50] [51] [52] With the more popular use of proton treatment, the cost-effectiveness comparisons between proton and X-ray treatment attract a lot of attention, especially on some specific sites such as left side breast cancer, head and neck cancer, pediatric cancer, and prostate cancer. [53] For left breast cancer and head and neck cancer, a series report by Lundkvist et al. showed incremental cost-effectiveness ratio (iCER, cost/life years gain) of 34290 and 3811, respectively. [54, 55] The assumption of their model included reducing the risks of ischemic heart disease, other cardiovascular diseases, and pneumonitis by proton treatment. For head and neck cancers, survival improvement and reduction of dental care cost were taken into account. In line with the widely accepted superiority of proton radiation in the prevention of long-term toxicity in childhood cancer, the evidence from pediatric medulloblastoma showed not only justified cost-effectiveness with higher quality-adjusted life years (QALY), but also lower costs (−$33,000). [50, 56] There was a lot of debate for the cost-effectiveness analysis of prostate cancer, usually evaluated with cost-effectiveness ratio (CER) or cost-utility analysis (CUA, cost/QALY). Both Lundkvist et al. and Konski et al. used Markov model, but reached dissimilar conclusions. [6, 55] The Swedish group reported an iCER of 26,776, but the US group found it the iCER to be between $63,578 for a 70-year-old man and $55,726 for a 60-year-old man. This difference may be attributed to the differences in the parameters set for analysis; these included: Younger age (65 vs. 70), different techniques of photon therapy (conventional conformal radiotherapy vs. IMRT), different incremental costs (7953 vs. $32,765), and different outcome estimates (20% reduction in overall cancer mortality with 20% reduction in the risk of adverse effect, and 7% improvement in quality of life vs. 10% increase in freedom from biological failure at 10 years without impact on quality of life). [49] Although the US group estimated over $50,000 per QALY for prostate cancer proton therapy, there was another voice about raising the cutoff point to $100,000, and to even $150,000, since the standard $50,000 has been used over two decades. [57] Most of the cost-effectiveness analyses were based on retrospective data; more prospective clinical trials are needed to validate the assumptions.
The clinical trial for proton therapy in Taiwan
As described above, primary liver tumor and head and neck cancer (including nasopharyngeal carcinoma and buccal cancer) are two diseases with high prevalence in Taiwan, but not in western countries; therefore, proton centers in Taiwan have a greater responsibility to conduct clinical trials in these cancers. For example, the comparisons between proton therapy and radiofrequency ablation in patients not candidates for surgical resection but with medium-sized tumor (3-7 cm) should form a trial that may have a great impact for the management of primary liver tumor. Another example is to compare the quality of life during and after treatment for NPC patients treated by IMPT or X-ray radiotherapy (IMRT). These two clinical trials will be conducted at our proton center, either by a single institution or with international cooperation.
Conclusions
In the United States, prostate cancer is the dominant type of cancer treated by proton therapy, but this might not be the case in Taiwan. Due to the unique pattern of cancer types in Taiwan, the proportion of patients (excluding prostate cancer) suitable for proton therapy is higher in Taiwan than in USA. More prospective studies should be conducted to demonstrate that the dosimetric benefit, in terms of sparing the normal tissues, could translate into clinical benefits to improve patients' lives and survival in some diseases.
